Source: EnWave Corp.
  • EnWave Corporation (ENW) has signed an agreement with a Canadian cannabis company to use its 10kW Radiant Energy Vacuum (REV) technology
  • The 10kW dehydration machine will be utilized for the drying cannabis flower and derivatives for the adult-use Canadian market at their primary cultivation and production facility in Canada
  • The Cannabis Cultivator will trial REV technology over six months to thoroughly evaluate all post-harvest improvements offered by EnWave’s patented technology
  • EnWave (ENW) is up by 1.49 per cent, and trading at $0.68 per share as of 9:45 am ET

EnWave Corporation (ENW) has signed an agreement with a Canadian cannabis company to use its 10kW Radiant Energy Vacuum (REV) technology.

The 10kW dehydration machine will be utilized for the drying cannabis flower and derivatives for the adult-use Canadian market at their main cultivation and production facility in Canada.

The cannabis cultivator will trial REV technology over a six-month period to evaluate all post-harvest improvements offered by EnWave’s patented technology.

Located at EnWave’s head office in Vancouver, Canada, the REVworx facility is the first large-scale vacuum-microwave toll processing facility in North America that exclusively offers third-party drying services. It can also allow companies to bring innovative vacuum-microwave dried products to market, enable growers to salvage and process imperfect produce, and reduce overall food waste.

EnWave Corporation licenses its REV technology, a proprietary method for dehydrating organic materials.

EnWave (ENW) is up by 1.49 per cent and trading at $0.68 per share as of 9:45 am ET.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.